Table 1 Ongoing preclinical and clinical trials utilizing ADC that target different antigens in the treatment of ovarian cancer

1

Preclinical

TROP-2

Cleavable 6.78

SN-38

Sacituzumab govitecan

[40, 41]

TIM1

Cleavable 4.5

Monomethyl auristatin E (MMAE)

CDX-014

[42]

PTK7

Cleavable NR

Microtubule/Tubulin inhibitor, PF-0664178 (Aur0101)

Cofetuzumab pelidotin

[43]

2

Phase 1

NOTCH-3

Cleavable NR

Monomethyl

PF-06650808

Praluzatamab

NCT02129205

[44]

CD166

Cleavable 3.5

Analogue of maytansine (DM4)

Ravtansine, CX-2009

NCT03149549

[45]

MUC16

Cleavable 3.5

MMAE

Sofituzumab vedotin

NCT01335958

[46]

NaPi2B

Cleavable ester linker

Auristatin F-hydroxypropylamide (AF-HPA)

Upifitamab rilsodotin

UPGRADE-A

NCT04907968

[47]

UPLIFT (NCT03319628) I-II

[47]

UP-NEXT (NCT05329545) III

[47]

Folate receptor α

Cathepsin cleavable linker

Eribulin

Farletuzumab ecteribulin

NCT04300556

[47]

Folate receptor α

Protease-labile Val-Cit-PABA linker

Hemiasterlin

Luveltamab tazevibulin

NCT05200364

[47]

3

Phase 2

Tissue factor

Cleavable 3.2

MMAE

Tisotumab vedotin

NCT03438396

[22]

Mesothelin

Cleavable 3.2

DM4

Anetumab ravtansine

NCT03587311

[48]

NaPi2B

Cleavable 3–4

MMAE

Lifastuzumab vedotin

DNIB0600A

[49]

Mesothelin

Sulfo-PDB

DM4

Anetumab ravtansine

NCT03587311

[47, 50]

Folate receptor α

Cathepsin cleavable linker

Eribulin

Farletuzumab ecteribbulin

NCT04300556

[47]

Folate receptor α

Sulfo-PDB cleavable linker

DM4

Mirvetuximab soravtansine

NCT04274426 NCT05041257

[47]

4

Phase 3

Folate receptor α

Sulfo-PDB cleavable linker

DM4

Mirvetuximab soravtansine

NCT04209855

[51]

Folate receptor α

Sulfo-PDB cleavable linker

DM4

Mirvetuximab soravtansine

NCT05445778

[47]